57 results
Page 2 of 3
8-K
EX-99.2
fgw8j
2 May 22
Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
6:04am
8-K
EX-99.1
lvtr0tkh 1pzvpg8f
23 Mar 22
Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Results to be presented in an oral presentation at a medical congress in 2Q 2022
4:03pm
424B5
fr2p8 vk8
14 Oct 21
Prospectus supplement for primary offering
4:07pm
424B5
ilab7pq ev
14 Oct 21
Prospectus supplement for primary offering
4:02pm
424B5
eb5dclx224od9h
12 Oct 21
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
n8dkb0 3cw7ea
23 Sep 21
Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021
2:53pm
8-K
EX-99.1
yr2m0u7ehvgx
13 Sep 21
Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Tracking to Announce Top line data in Q1 2022
12:11pm
424B5
nkj8fu6t
4 Aug 21
Prospectus supplement for primary offering
12:00am
8-K
EX-10.1
hwmy5z
4 Aug 21
Entry into a Material Definitive Agreement
12:00am
8-K
EX-10.1
fbyeg9 w5dffw
9 Oct 20
Rezolute Announces $41 Million Private Placement with Leading Investment Firms and Prepares to Imminently Up-list to Nasdaq
7:02pm
POS AM
8uzssjsm03rq67
14 Oct 16
Prospectus update (post-effective amendment)
12:00am
POS AM
afvh0ssz6dcu
14 Oct 16
Prospectus update (post-effective amendment)
12:00am